ClinicalTrials.gg
RecruitingNCT05582772TOPCOP3Updated Jul 3, 2025

TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

An interventional study of GA+M Intervention and RSM intervention in Metastatic Prostate Cancer, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to male participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
65 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 102 studies in Prostatic Neoplasms by University Health Network, Toronto — 23 open to participants now, 29 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.

Planned enrollment
13th of 86
168 · median 44
Started
2023
with 3 others
No phase
44 of 102
13 open now
Primary completion
2027-02
later than 5 of 28 live
Registered
88th of 102
by date

Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 13th largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2023, is one of 44 with no phase, reaches primary completion later than 5 of the 28 other live ones, and was the 88th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

23 of the 102 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 65 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Prostatic Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

TOPCOP3 is a pilot factorial RCT of geriatric assessment and management, remote symptom monitoring, both interventions or neither, accompanied by an embedded process evaluation. This design is widely used to guide the evaluation of complex interventions and provides important data to aid design of larger RCTs. The trial itself falls within pilot trial goals including obtaining variance estimates for outcomes, assessment of recruitment potential, and understanding implementation issues vital to designing a larger trial. The investigators have clear feasibility objectives and an analytic plan as well as criteria to determine success and strong support from cancer advocacy and policy groups.

Read the detailed description

Emerging data from supportive care intervention trials in people receiving chemotherapy suggest 2 different approaches - geriatric assessment and management (GA+M) and remote symptom monitoring (RSM) - may be associated with improved time on treatment, improved QOL, reduced toxicity, reduced unplanned health care use, and possibly prolonged overall survival. These 2 interventions have not been tested in combination or in people receiving treatments other than chemotherapy (such as ARATs). This RCT includes an embedded process evaluation of GA+M and RSM versus usual care to gather key efficacy and implementation data needed to design a definitive phase III RCT.

The next logical step in our research program is an intervention examining GA+M, RSM, or the combined intervention to improve the health and treatment tolerability for older men with mPC on ARATs. The pilot trial will gather key clinical outcome and feasibility data needed to inform a definitive phase III RCT; a necessary step in providing clinicians a greatly needed evidence-based supportive care intervention. The intervention was designed in partnership with patients and knowledge users, which will result in more relevant findings and greater health impact.

A total of 168 patients will be enrolled in the RCT across 2 centres. Based on TOPCOP1 and TOPCOP2, both of which included the two centres in TOPCOP3, the recruitment rate was 2-3 patients per week. There are 3-5 eligible patients per week across the two sites. Assuming a conservative recruitment rate of 50%, the investigators expect recruitment for this study to take 18 months.

Randomization will be centralized using REDCap, a secure web-based electronic data entry system. Patients will be allocated in a 1:1:1:1 ratio to GA+M, RSM, combined, or control, with stratification by mPC subtype (castration-sensitive or resistant) following recommended guidelines on number of strata. Permuted blocks of variable size will be used.

Given the nature of the intervention, it is not possible to blind patients or the project team to allocation. However, participants will be randomized, allocation will be concealed, variable permuted blocks will be used, 1 of the 2 co-primary outcomes will be assessed by blinded assessors (toxicity), validated measures will be used, several outcomes will be verified by independent data collection (treatment toxicity, overall survival), and the trial statistician will be blinded during the trial and during analysis of the main study results, similar to our 5C trial.

GA+M intervention arm:

All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol.

Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C.Telephone follow-ups at 1, 3 and 6 months by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed.

RSM Intervention arm:

All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit symptoms. In our prior study, almost half the participants preferred telephone calls. If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. For moderate symptoms that persist even after follow up, if the RSM nurse feels that the patient is clinically stable in the same symptom based on at least 2 phone assessments, 1 week apart, and there are no further COSTaRS-directed interventions to be implemented for this symptom based on the RSM nurse's judgement the following silencing protocol can be adopted: The RSM nurse will inform the study coordinator to not flag the study nurse for further moderate alerts for the same symptom if the score is identical to the prior week (i.e. to silence the alarm). If the score changes from moderate to severe, or increases 2 points within the same verbal descriptor severity category (e.g. 4 to 6/10, both are moderate) then the nurse is alerted again. The silencing option will remain for 4 weeks then expire. Symptom monitoring will continue for 6 months or discontinuation of treatment (whichever comes first). If treatment is discontinued for a period of 3 weeks, the weekly ESAS questionnaire will not be sent out to the participant until treatment is resumed. An escalation protocol will also be followed for persistent symptoms or those deemed out of scope for nurse-guided self-management, with referral to the patient's oncologist or urgent care as appropriate. Oncology nurses are ideally situated to be the primary point of contact with oncology patients, can promote patient self-efficacy, provide counselling and support, and can handle 87% of issues without needing physician input.

GA+RSM Combination:

Participants will receive both strategies as detailed above, with a GA at baseline.

Control:

Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line.

Patients will receive the TOPCOP3 intervention for a duration of 6 months. This balances participant burden and resources with a timeframe that is sufficient to observe clinical and implementation outcomes (most severe toxicity is observed within the first 3 months of treatment. Most GA+M trials have been 6 months in duration.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Geriatric assessment
  • ARAT
  • Supportive Care
  • Older men
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Starting an ARAT or started an ARAT within 2 weeks prior to being approached or switching ARATs due to progression or toxicity
  2. Diagnosed with mPC (castration-sensitive or resistant) or nmCRPC (non- castration-resistant prostate cancer)
  3. At least 65 years old
  4. Able to provide written
  5. Has a working telephone

Exclusion criteria

Exclusion Criteria:

  1. Unable to speak English (as contact with the nurse interventionist is via phone, not all outcome measures are available in multiple languages)
  2. Major neuropsychiatric abnormalities (severe depression or moderate-severe dementia)
  3. \<3 months as estimated by the oncologist
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Active comparator
    GA+M Intervention

    GA+M intervention arm All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol. Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C. Telephone follow-ups at 1, 3 and 6 months by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed.

    Other: GA+M Intervention

  • Active comparator
    RSM Intervention

    RSM Intervention All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. Symptom monitoring will continue for 6 months or discontinuation of treatment.

    Other: RSM intervention

  • Active comparator
    GA+RSM intervention

    GA+RSM Combination Participants will receive both strategies as detailed above, with a GA at baseline.

    Other: GA+RSM intervention

  • No intervention
    Control

    Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.

Interventions

  • OtherGA+M Intervention

    Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.

    Also known as: Geriatric assessment and management

  • OtherRSM intervention

    Telephone-based, symptom management of patients with cancer

    Also known as: Remote symptom monitoring

  • OtherGA+RSM intervention

    Combining a geriatric assessment and remote symptom control

    Also known as: Geriatric assessment and remote symptom monitoring

06

What researchers measure

Primary outcomes

  1. Number of participants with Grade 3-5 Toxicity

    Grade 3-5 toxicity. This will be coded as at least one grade 3-5 toxicity vs none, measured based on review of clinical notes supplemented by interviews with patients by trained research staff and verified by a blinded physician. Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: 6 months

  2. Health related quality of life in patients with metastatic prostate cancer

    QOL will be measured by patient self-report using the EQ-5D-5L, which is the EuroQol 5 dimensions of health questionnaire. This is a widely used, psychometrically valid brief generic QOL questionnaire.

    Time frame: 6 months

Secondary outcomes

  1. Number of patients with treatment discontinuation

    Early treatment discontinuation due to toxicity. This will be based on chart review and oncologist clarification.

    Time frame: 6 months

  2. Number of patients with treatment modification

    Treatment modification after GA (change in ARAT dose/agent). Based on chart review. For GA+M arms only

    Time frame: 6 months

  3. Number of patients with severe symptoms

    Symptom severity. This is measured using the 15-item Symptom Distress Scale. This is a patient reported outcome (PRO).

    Time frame: 6 months

  4. Number of patients with decline in Instrumental Activities of Daily Living (IADL)

    Decline in IADL using the Older Adults Resources and Services (OARS) scale. This is a patient reported outcome (PRO).

    Time frame: 6 months

  5. Number of patients with unplanned health care

    Unplanned health care use. Emergency room visits and hospital admissions will be recorded at each time point with a combination of patient interviews and electronic health record audit

    Time frame: 6 months

  6. Fatigue

    Fatigue - measured using the Brief Fatigue Inventory (BFI). This is a patient reported outcome (PRO).

    Time frame: 6 months

  7. Insomnia

    Insomnia will be measured using the Insomnia Severity Index. This is a patient reported outcome (PRO).

    Time frame: 6 months

  8. Anorexia and cachexia

    Anorexia and Cachexia is measured with the Functional Assessment of Anorexia-Cachexia Therapy scale (Functional Assessment of Anorexia/Cachexia FAACT-A/CS-12). This is a patient reported outcome (PRO).

    Time frame: 6 months

  9. Depression

    Depression will be measured using the 9-item Patient Health Questionnaire (PHQ-9). This is a patient reported outcome (PRO).

    Time frame: 6 months

Other outcomes

  1. Process evaluation: Feasibility

    The trial will be determined to be feasible if recruitment rate is 60% or higher, retention rate is 85% or higher, adherence is 90% or higher, outcome capture is 90% or higher, and contamination rate is 5% or less.

    Time frame: 6 months

  2. Process evaluation: Acceptability

    Likert scale satisfaction survey.

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
  • St. Michael's hospital
    Toronto, Ontario M5B 1W8, Canada
    Recruiting
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C1, Canada
    Recruiting
    • Shabbir Alibhai, MD · Contactshabbir.alibhai@uhn.ca · 4163405125
    • Soha Abdallah · Contactsoha.abdallah@uhn.ca · 416-946-4501
    • Shabbir Alibhai, MD · Principal investigator
    • Jacqueline Bender, PhD · Sub investigator
    • Alejandro Berlin, MD · Sub investigator
    • Antonio Finelli, MD · Sub investigator
    • Rana Jin, RN, Msc · Sub investigator
    • Monika Krzyzanowska, MD, MPH · Sub investigator
    • Calvin Mach, RD, MPH · Sub investigator
    • Andrew Matthew, PhD · Sub investigator
    • Lesley Moody, PhD · Sub investigator
    • Efthymios Papadopoulos, PhD · Sub investigator
    • Enrique Soto Perez de Celis, MD · Sub investigator
    • Srikala Sridhar, MD · Sub investigator
    • George Tomlinson, PhD · Sub investigator
    • Rachel Glicksman, MD · Sub investigator
    • Martine Puts, RN · Principal investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Recruiting
    • Urban Emmenegger, MD · Contacturban.emmenegger@sunnybrook.ca · 416-480-4928
    • Urban Emmenegger, MD · Principal investigator
    • Daniel Khalaf, MD · Sub investigator
08

References and documents

Publications

  • Alibhai SMH, Puts M, Jin R, Godhwani K, Antonio M, Abdallah S, Feng G, Krzyzanowska MK, Soto-Perez-de-Celis E, Papadopoulos E, Mach C, Nasiri F, Sridhar SS, Glicksman R, Moody L, Bender J, Clarke H, Matthew A, McIntosh D, Klass W, Emmenegger U. TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation. J Geriatr Oncol. 2024 Jul;15(6):101750. doi: 10.1016/j.jgo.2024.101750. Epub 2024 Mar 23. PubMed 38521641 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2027, 45 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 45 months is close to that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Oct 17, 2022
StartActual
May 23, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05582772
Collaborators
Rising Tide Foundation
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
May 23, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Shabbir Alibhai, MD
Contact
shabbir.alibhai@uhn.ca
(416) 340-5125
Soha Abdallah, PhD
Contact
soha.abdallah@uhn.ca
416-946-4501 ext. 3926
Shabbir Alibhai, MD
principal investigator · UHN - Princess Margaret Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion